311 results on '"Beider, Katia"'
Search Results
2. A polygenic risk score for multiple myeloma risk prediction
3. CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
4. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma
5. Mesenchymal Stromal Cells regulate human Hematopoietic Stem Cell survival and regeneration via cAMP/PKA pathway
6. Genetically determined telomere length and multiple myeloma risk and outcome
7. P854: EFFECT OF HPSE AND HPSE2 SNPS ON THE RISK OF DEVELOPING PRIMARY PARASKELETAL MULTIPLE MYELOMA
8. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response
9. Supplementary Figure 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
10. Supplementary Figure 2 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
11. Supplementary Table 1 from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
12. Data from Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo
13. Table S3 from Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers
14. Figure S5 from CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
15. Supplementary Figure 3 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
16. Supplementary Figure 1 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
17. Supplementary Figure 2 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
18. Supplementary Tables 1 - 5 from The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
19. Supplementary Figure 4 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
20. Supplementary Figure 5 from Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140
21. Effect of HPSE and HPSE2 SNPs on the Risk of Developing Primary Paraskeletal Multiple Myeloma
22. Multiplex HDR for disease and correction modeling of SCID by CRISPR genome editing in human HSPCs
23. CRISPR-Cas9 RAG2 Correction via Coding Sequence Replacement to Preserve Endogenous Gene Regulation and Locus Structure
24. Extracellular Vesicles Released By Anti-Human Thymocyte Globulins (ATG)-Exposed Mononuclear Cells Can Contribute to Immune Modulation in Allogeneic Stem Cell Transplantation
25. GATA6-AS1 regulates intestinal epithelial mitochondrial functions, and its reduced expression is linked to intestinal inflammation and less favorable disease course in ulcerative colitis (UC)
26. CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma
27. Multiplex HDR for Disease and Correction Modeling of SCID by CRISPR Genome Editing in Human HSPCs
28. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
29. Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies
30. Additional file 1 of CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression
31. Identification of miRSNPs associated with the risk of multiple myeloma
32. Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
33. The Phenotypic, Transcriptional and Functional Properties of CAR T Cells Products May Predict Response of Patients with B Cell Lymphoid Malignancies Treated with CD19 CAR-T Cells
34. High-Throughput Imaging of CRISPR- and Recombinant Adeno-Associated Virus–Induced DNA Damage Response in Human Hematopoietic Stem and Progenitor Cells
35. Ccr5 deficiency regulates the proliferation and trafficking of natural killer cells under physiological conditions
36. CMV Seropositive Status Increases Heparanase SNPs Regulatory Activity, Risk of Acute GVHD and Yield of CD34+ Cell Mobilization
37. A polygenic risk score for multiple myeloma risk prediction
38. Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma
39. The HPSE Gene Insulator—A Novel Regulatory Element That Affects Heparanase Expression, Stem Cell Mobilization, and the Risk of Acute Graft versus Host Disease
40. Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions
41. 226 - Interleukin-8 Serum Levels - a Surrogate Marker for Pseudo-Tumor Progression Post Anti-CD19 Chimeric Antigen Receptor T Cells Treatment in Aggressive B-Cell Lymphoma
42. OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients
43. Interleukin-8 Serum Levels - a Surrogate Marker for Pseudo-Tumor Progression Post Anti-CD19 Chimeric Antigen Receptor T Cells Treatment in Aggressive B-Cell Lymphoma
44. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production
45. A polygenic risk score for multiple myeloma risk prediction:E-poster
46. Additional file 1 of Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response
47. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma
48. Common gene variants within 3′‐untranslated regions as modulators of multiple myeloma risk and survival
49. 324 - Extracellular Vesicles Released By Anti-Human Thymocyte Globulins (ATG)-Exposed Mononuclear Cells Can Contribute to Immune Modulation in Allogeneic Stem Cell Transplantation
50. Inflammation-Induced Hepatocellular Carcinoma Is Dependent on Ccr5 in Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.